Menu Menu


AZN Financials       Clear


AZN        0000901832    
Filing Date Form Type Description Document
2022-08-30 6-K EVUSHELD APPROVED FOR COVID-19 IN JAPAN View Document
2022-08-30 6-K FARXIGA REDUCED RISK OF CV DEATH OR WORSENING HF View Document
2022-08-30 6-K FARXIGA SHOWS CV MORTALITY BENEFIT ACROSS EF RANGE View Document
2022-08-25 6-K ULTOMIRIS APPROVED IN JAPAN FOR GMG View Document
2022-08-25 6-K TAGRISSO APPROVED IN JAPAN FOR EARLY LUNG CANCER View Document
2022-08-25 6-K LYNPARZA APPROVED IN JAPAN FOR EARLY BREAST CANCER View Document
2022-08-16 6-K LYNPARZA GRANTED FDA PRIORITY REVIEW FOR PROPEL View Document
2022-08-15 6-K ENHERTU IMPROVED PFS IN MBC IN DESTINY-BREAST02 View Document
2022-08-12 6-K ENHERTU APPROVED IN US FOR HER2-MUTANT NSCLC View Document
2022-08-11 6-K ACQUISITION OF TENEOTWO COMPLETED View Document
2022-08-08 6-K ENHERTU APPROVED IN THE US FOR HER2-LOW MBC View Document
2022-08-04 6-K LYNPARZA APPROVED IN EU FOR EARLY BREAST CANCER View Document
2022-08-01 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-08-01 6-K TOTAL VOTING RIGHTS View Document
2022-08-01 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-07-29 6-K FORM 6-K View Document
2022-07-29 6-K CHAIR SUCCESSION View Document
2022-07-25 6-K TEZSPIRE RECOMMENDED FOR EU APPROVAL IN ASTHMA View Document
2022-07-25 6-K ULTOMIRIS RECOMMENDED FOR EU APPROVAL FOR GMG View Document
2022-07-25 6-K ENHERTU GRANTED PRIORITY REVIEW FOR HER2-LOW MBC View Document
2022-07-19 6-K ENHERTU APPROVED IN EU FOR HER2-POSITIVE MBC View Document
2022-07-08 SC 13G View Document
2022-07-05 6-K ASTRAZENECA TO ACQUIRE TENEOTWO AND T CELL ENGAGER View Document
2022-07-01 6-K TOTAL VOTING RIGHTS View Document
2022-06-30 6-K IMFINZI IMPROVED PCR IN RESECTABLE LUNG CANCER View Document
2022-06-29 11-K ANNUAL REPORT View Document
2022-06-27 6-K ENHERTU RECOMMENDED FOR BREAST CANCER EU APPROVAL View Document
2022-06-27 6-K LYNPARZA RECOMMENDED IN EU FOR EARLY BREAST CANCER View Document
2022-06-21 6-K EPLONTERSEN PH III TRIAL MET CO-PRIMARY ENDPOINTS View Document
2022-06-10 25-NSE View Document
2022-06-09 25-NSE View Document
2022-06-06 6-K ENHERTU EFFICACY RESULTS IN HER2-LOW BREAST CANCER View Document
2022-06-01 6-K BLOCK LISTING INTERIM REVIEW View Document
2022-06-01 6-K TOTAL VOTING RIGHTS View Document
2022-05-20 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-05-09 6-K APPOINTMENT OF JOINT CORPORATE BROKERS View Document
2022-05-06 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-05-05 6-K ENHERTU APPROVED IN US FOR 2L HER2+ BREAST CANCER View Document
2022-05-05 6-K FARXIGA HFPEF PHASE III TRIAL MET PRIMARY ENDPOINT View Document
2022-05-05 6-K ULTOMIRIS NMOSD PH. III TRIAL MET PRIMARY ENDPOINT View Document
2022-05-04 6-K IMFINZI COMBO GRANTED PRIORITY REVIEW FOR BTC View Document
2022-05-03 6-K TOTAL VOTING RIGHTS View Document
2022-04-29 6-K RESULT OF AGM View Document
2022-04-29 6-K ASTRAZENECA PLANS NEW R&D CENTRE IN MASSACHUSETTS View Document
2022-04-29 6-K FIRST QUARTER 2022 RESULTS View Document
2022-04-28 6-K ULTOMIRIS APPROVED IN THE US FOR ADULTS WITH GMG View Document
2022-04-27 6-K ENHERTU GRANTED BTD FOR HER2-LOW BREAST CANCER View Document
2022-04-25 6-K TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBO View Document
2022-04-19 6-K ENHERTU GRANTED PRIORITY REVIEW FOR HER2M NSCLC View Document
2022-04-01 6-K TOTAL VOTING RIGHTS View Document
2022-03-29 6-K ONDEXXYA APPROVED IN JAPAN FOR FXAI REVERSAL View Document
2022-03-28 6-K EVUSHELD APPROVED IN THE EU FOR COVID-19 View Document
2022-03-25 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-03-24 6-K EVUSHELD POSITIVE EU CHMP OPINION View Document
2022-03-24 6-K UPDATE ON CALLA PHASE III TRIAL OF CONCURRENT USE OF IMFINZI AND CHEMORADIOTHERA View Document
2022-03-23 6-K NOTICE OF AGM View Document
2022-03-23 6-K FORM 6-K View Document
2022-03-17 6-K SETTLEMENT OF PATENT LITIGATION FOR ULTOMIRIS View Document
2022-03-14 6-K LYNPARZA APPROVED IN US FOR EARLY BREAST CANCER View Document
2022-03-14 6-K UPDATE ON US REVIEW OF FASENRA IN NASAL POLYPS View Document
2022-03-09 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-03-07 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-03-01 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-03-01 6-K TOTAL VOTING RIGHTS View Document
2022-03-01 6-K ASTRAZENECA AND NEURIMMUNE CLOSE DEAL FOR NI006 View Document
2022-02-23 6-K FILING OF FORM 20-F WITH SEC View Document
2022-02-22 IRANNOTICE IRANNOTICE View Document
2022-02-22 20-F FORM 20F View Document
2022-02-22 6-K CHAIR SUCCESSION PLANNING UPDATE AND ANNUAL REPORT View Document
2022-02-22 6-K ENHERTU IMPROVES PFS AND OS IN HER2-LOW BC View Document
2022-02-16 6-K SAPHNELO APPROVED IN EU FOR SLE View Document
2022-02-15 6-K LYNPARZA COMBO DELAYS PROGRESSION RISK IN PROSTATE View Document
2022-02-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-02-10 6-K AZN: FULL YEAR AND Q4 2021 RESULTS View Document
2022-02-07 SC 13G/A View Document
2022-02-04 SC 13G/A SEC SCHEDULE 13G View Document
2022-02-01 6-K TOTAL VOTING RIGHTS View Document
2022-01-19 6-K IMFINZI IMPROVES SURVIVAL IN BILIARY TRACT CANCER View Document
2022-01-19 6-K IMFINZI COMBO SHOWS UNPRECEDENTED SURVIVAL IN HCC View Document
2022-01-18 6-K ENHERTU GRANTED PRIORITY REVIEW FOR BREAST CANCER View Document
2022-01-07 6-K ASTRAZENECA AND NEURIMMUNE SIGN DEAL FOR NI006 View Document
2022-01-05 6-K TRANSFER OF RIGHTS TO EKLIRA, DUAKLIR COMPLETED View Document
2022-01-04 6-K TOTAL VOTING RIGHTS View Document
2021-12-29 6-K ASTRAZENECA AND IONIS CLOSE EPLONTERSEN DEAL View Document
2021-12-21 6-K ULTOMIRIS ACCEPTED FOR FDA PRIORITY REVIEW FOR GMG View Document
2021-12-20 6-K TEZSPIRE APPROVED IN THE US FOR SEVERE ASTHMA View Document
2021-12-20 6-K SAPHNELO RECOMMENDED FOR EU APPROVAL FOR SLE View Document
2021-12-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2021-12-09 6-K EVUSHELD US FDA EUA View Document
2021-12-07 6-K ASTRAZENECA, IONIS TO COLLABORATE ON EPLONTERSEN View Document
2021-12-01 6-K BLOCK LISTING INTERIM REVIEW View Document
2021-12-01 6-K TOTAL VOTING RIGHTS View Document
2021-11-30 6-K LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIA View Document
2021-11-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2021-11-12 6-K AZN: YEAR TO DATE AND Q3 2021 RESULTS View Document
2021-11-01 6-K TOTAL VOTING RIGHTS View Document
2021-11-01 6-K ASTRAZENECA TO TRANSFER RIGHTS TO EKLIRA, DUAKLIR View Document
2021-10-25 6-K IMFINZI IMPROVED SURVIVAL IN BILIARY TRACT CANCER View Document
2021-10-18 6-K AZ RECOMMENDS ADS HOLDERS REJECT MINI-TENDER OFFER View Document
2021-10-15 6-K IMFINZI & TREMELIMUMAB IMPROVED OS IN LIVER CANCER View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

(402) 804-8299